Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech fireworks -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1365)	12/17/2003 4:08:41 PM
From: Jibacoa	Respond to of 7424

VLGC Is up 20.4% on volume of 5M about 5x its daily average. It is presenting results of its HCV drug susceptibility assay with applications in drug development at the 5th biennial HepDART meeting "Frontiers in Drug Development for Viral Hepatitis" which is being held in Kauai, Hawaii, December 14-18. "Recent research advances have boosted understanding of Hepatitis C virus replication and provided the biopharmaceutical industry with several new targets for potential therapeutic intervention," said Bill Young, ViroLogic's Chairman and Chief Executive Officer. "The HepDART presentation illustrates how ViroLogic's expertise in virology and assay development can be applied to facilitate the development of therapeutics for the treatment of this serious chronic disease." The study entitled, "Sequence Analysis of NS5B in Genotype 1 HCV: Extensive Sequence Variability and Naturally Occurring Polymorphisms Which May Affect Polymerase Inhibitor Activity" characterized the natural genetic variation in HCV polymerase (NS5B) using ViroLogic's newly developed genotyping assay. The assay is currently available to biopharmaceutical companies for generation of clinical data for evaluation of a promising new class of anti-HCV drugs that target the viral polymerase. bigcharts.marketwatch.com Bernard